Lacosamid Ratiopharm (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. By stabilising these channels in an inactive state, it limits repetitive neuronal firing and reduces hyper‑excitability, which are key mechanisms underlying seizure generation.

The specific dose of Lacosamid Ratiopharm is determined by the prescribing clinician based on the patient’s age, renal and hepatic function, and response to therapy. Dosage adjustments are made individually; no fixed regimen is provided in public information.

Safety data for lacosamide during pregnancy and lactation are limited. The drug should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lacosamide belongs to the sodium‑channel blocker class and is distinguished by its selective enhancement of slow channel inactivation. Compared with older sodium‑channel blockers such as carbamazepine, lacosamide has a different interaction profile and may be better tolerated in some patients, but individual response varies and choice depends on clinical factors.

Lacosamid Ratiopharm should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct light to maintain potency throughout its shelf life.

Lacosamid Ratiopharm is taken orally, usually as a tablet. It is swallowed whole with water and can be taken with or without food, following the dosing schedule prescribed by the treating physician.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, suicidal ideation or behavior, severe skin reactions (e.g., Stevens‑Johnson syndrome), hepatic dysfunction, hypersensitivity reactions including anaphylaxis, and rare blood disorders like agranulocytosis. Patients should be monitored for these events.

Lacosamid is contraindicated in patients with known hypersensitivity to lacosamide or any component of the formulation. Caution is advised for individuals with significant cardiac conduction disorders, severe hepatic impairment, or those taking strong enzyme‑inducing antiepileptics that markedly reduce lacosamide levels.